Skip to main content

Table 1 CYP26A1 expression and the clinical profiles of the cervical cancer tissue microarray

From: Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer

  

CYP26A1 expression

 

Variables

Cases (n)

Negative (%)

Positive (%)

P

Age (years)

    

  <50

21

9 (42.9)

12 (57.1)

0.022*

  ≥50

29

22 (75.9)

7 (24.1)

 

Primary tumor status (pT)

    

  pTis

3

2 (66.7)

1 (33.3)

0.076

  pT1a

7

7 (100)

0 (0)

 

  pT1b

35

18 (51.4)

17 (48.6)

 

  pT2

5

4 (80.0)

1 (20.0)

 

Lymph node involvement (pN)

    

  Absent

31

24 (77.4)

7 (22.6)

0.016*

  Present

19

8 (42.1)

11 (57.9)

 

pTNM stage

    

  pStage 0

3

2 (66.7)

1 (33.3)

0.061

  pStage IA

7

7 (100)

0 (0)

 

  pStage IB

20

13 (65.0)

7 (35.0)

 

  pStage II

1

1 (100)

0 (0)

 

  pStage III

19

8 (42.1)

11 (57.9)

 

p53 expression

    

  Absent

44

25 (56.8)

19 (43.2)

0.071

  Present

6

6 (100)

0 (0)

 

Ki-67 labeling index

    

  <20%

35

25 (71.4)

10 (28.6)

0.056

  ≥20%

15

6 (40.0)

9 (60.0)

 
  1. *Significantly different by the chi-square (χ2) test.
  2. Abbreviations: CYP26A1, cytochrome P450, family 26, subfamily A, polypeptide 1; pTNM, pathological tumor-node-metastasis